AB 641 California Assembly · 2025-2026 Regular Session

Drug-Induced Movement Disorder Awareness Program.

Summary

Existing law requires the State Department of Public Health to conduct various programs related to disease prevention and health promotion, including a program for identifying, screening, and providing followup care related to exposure to diethylstilbestrol while pregnant, which can cause fetal abnormalities. Existing law states the intention of the Legislature to fund this program in subsequent fiscal years through the normal budgetary process. This bill would direct, upon appropriation of funds, as specified, the State Department of Public Health, by January 1, 2028, to develop and administer a program related to drug-induced movement disorder awareness, as specified. The bill would repeal the program on January 1, 2032. The bill would include related findings and declarations.

Issues: ✓ Healthcare

Bill status failed 1 of 4 stages cleared

Introduction

Feb 2025

Committee Review

Floor Vote

Governor

Introduced Feb 13, 2025 Last action Feb 2, 2026

Maddy AI version diff · 3 comparisons

What changed between versions

04/10/25 - Amended Assembly → AB641 · 1 edit

MINOR

This diff reflects a change in document format rather than substantive policy. The bill text moved from a traditional print-style legislative layout (with line numbers and page headers) to a web-based presentation format. The operative provisions of AB 641, including deadlines, program requirements, and repeal dates, remain unchanged between the two versions.

TECHNICAL

The document was reformatted from a traditional legislative print layout with line numbers and page headers into a web-based bill text format. No changes to the actual statutory language, deadlines (January 1, 2027/2028), repeal dates (January 1, 2031/2032), or program requirements were made.

03/19/25 - Amended Assembly → 04/10/25 - Amended Assembly · 6 edits · Apr 10, 2025

MODERATE

The April 10 amendment adds a co-author (Assembly Member Mark Gonzalez) and introduces a new parallel program for drug-induced movement disorder awareness under a different section of the Health and Safety Code (Division 103, Chapter 5, Section 104895.5) with a later deadline of January 1, 2028 and a sunset date of January 1, 2032. The original program (Division 106, Chapter 2, Section 125711) is retained with its earlier 2027 deadline and 2031 sunset. The new program has a narrower scope, requiring only evidence-based educational information (including risk factors) and stigma-reduction outreach, while dropping the requirement for clinical standards guidance on telehealth.

SCOPE

A new program (Section 104895.5 in Division 103) is added alongside the existing program (Section 125711 in Division 106), effectively creating two parallel drug-induced movement disorder awareness programs with different timelines and slightly different requirements.

TIMELINE

The new program has a development deadline of January 1, 2028 (one year later than the original program's 2027 deadline) and sunsets on January 1, 2032 (one year later than the original's 2031 sunset).

REQUIREMENT

The new program requires only two components: evidence-based educational information on screening, identifying symptoms, and risk factors; and education/outreach to eliminate stigma. The original program's requirement for developing clinical standards guidance (including telehealth) is not included in the new program.

ELIGIBILITY

The new program allows CDPH to consult with the State Department of Health Care Services and the Behavioral Health Services Oversight and Accountability Commission during implementation, adding interagency coordination not present in the original.

DEFINITION

The new program's educational requirements specifically include 'risk factors for developing drug-induced movement disorders,' which was not explicitly required in the original program.

TECHNICAL

A co-author (Assembly Member Mark Gonzalez) is added to the bill, and the legislative counsel's digest is updated to reference the existing diethylstilbestrol exposure program as contextual background.

Floor votes

How they voted

No floor votes recorded yet.

Full legislative history

Actions timeline

Total actions

Key actions

Committee

Amendments

Feb 2, 2026

Lower · Passed

From committee: Filed with the Chief Clerk pursuant to Joint Rule 56.

lower

May 23, 2025

Lower · Passed

In committee: Held under submission.

lower

Apr 30, 2025

Committee

In committee: Set, first hearing. Referred to suspense file.

lower

Apr 21, 2025

Committee

Re-referred to Com. on APPR.

lower

Apr 10, 2025

Lower · Passed

Read second time and amended.

lower

Apr 9, 2025

Introduced

From committee: Amend, and do pass as amended and re-refer to Com. on APPR. with recommendation: To Consent Calendar. (Ayes 15. Noes 0.) (April 8).

lower

Mar 20, 2025

Committee

Re-referred to Com. on HEALTH.

lower

Mar 19, 2025

Introduced

From committee chair, with author's amendments: Amend, and re-refer to Com. on HEALTH. Read second time and amended.

lower

Feb 24, 2025

Committee

Referred to Com. on HEALTH.

lower

Feb 14, 2025

Lower · Passed

From printer. May be heard in committee March 16.

lower

1 primary · 1 co-sponsor